Referencias bibliográficas
Rodríguez, P. C., Popa, X., Martínez, O., Mendoza, S.,Santiesteban, E., Crespo, T., ... & Neninger, E. (2016). A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non–small cell lung cancer patients. Clinical Cancer Research, 22(15), 3782-3790.
Evans, R., Lee, K., Wallace, P. K., Reid, M., Muhitch, J., Dozier, A., ... & Dy, G. K. (2022). Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC. Frontiers in Oncology, 12, 958043.
Frascati, R. et al. (2023). Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). JCO 41, 9135-9135.